Genprex Exec to Seek Industry Partnerships at BIO 2026
Event summary
- Genprex's SVP of Intellectual Property and Licensing, Thomas Gallagher, will attend BIO 2026 in San Diego (June 22-25) for one-on-one meetings with industry groups.
- The company is seeking partnerships to advance its gene therapies for cancer and diabetes.
- Genprex's lead product, Reqorsa® Gene Therapy, is in clinical trials for NSCLC and SCLC with FDA Fast Track and Orphan Drug designations.
- The company's diabetes program uses AAV vectors to deliver Pdx1 and MafA genes to the pancreas.
The big picture
Genprex's participation at BIO 2026 underscores the strategic importance of industry conferences for biotech firms seeking partnerships to scale clinical-stage therapies. The company's focus on cancer and diabetes aligns with growing demand for innovative treatments in these areas, particularly as gene therapy technologies advance. Success in securing collaborations could significantly impact Genprex's development timelines and market positioning.
What we're watching
- Partnership Potential
- Whether Genprex can secure meaningful collaborations at BIO 2026 to accelerate its clinical programs.
- Regulatory Momentum
- The pace at which Genprex advances its FDA-designated programs through clinical trials.
- Market Positioning
- How Genprex differentiates itself in the competitive gene therapy space for cancer and diabetes.
Related topics